Tag: Zolgensma

Novartis

Novartis stands behind Zolgensma® for the treatment of children less than 2 years of age with spinal muscular atrophy

Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma. The FDA supports the continued marketing and use of Zolgensma for patients with spinal muscular…